Literature DB >> 11360024

Effect of mild therapeutic hypothermia on phenytoin pharmacokinetics.

Y Iida1, S Nishi, A Asada.   

Abstract

The authors examined the effect of mild therapeutic hypothermia on phenytoin pharmacokinetics in 14 patients with brain damage. Each patient was given phenytoin during and after mild therapeutic hypothermia. Plasma concentrations of total phenytoin, unbound phenytoin, and 5-(p-hydroxyphenyl)-5-phenylhydantoin (5-p-HPPH), the major metabolite of phenytoin, were measured. Pharmacokinetic parameters during and after mild therapeutic hypothermia were compared. Plasma concentrations of total and unbound phenytoin were significantly higher during hypothermia than after hypothermia. The area under the plasma concentration-time curve (zero to infinity) was increased by 180% and mean residence time was prolonged by 180% during hypothermia compared with the corresponding values after hypothermia. Moreover, the elimination constant (ke) was decreased by 50% and elimination clearance of phenytoin was decreased by 67% during hypothermia compared with the corresponding values after hypothermia. The plasma concentration of 5-p-HPPH was significantly lower during hypothermia than after hypothermia. These findings suggest that phenytoin metabolism is inhibited by mild therapeutic hypothermia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11360024     DOI: 10.1097/00007691-200106000-00002

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  14 in total

Review 1.  Physiologic and pharmacologic considerations for hypothermia therapy in neonates.

Authors:  S Zanelli; M Buck; K Fairchild
Journal:  J Perinatol       Date:  2010-12-23       Impact factor: 2.521

2.  Mild hypothermia decreases fentanyl and midazolam steady-state clearance in a rat model of cardiac arrest.

Authors:  Philip E Empey; Tricia M Miller; Ashley H Philbrick; John A Melick; Patrick M Kochanek; Samuel M Poloyac
Journal:  Crit Care Med       Date:  2012-04       Impact factor: 7.598

3.  Phenytoin-induced hypothermia.

Authors:  Marianne Watters; Hilary Wilson; Pamela Everitt
Journal:  BMJ Case Rep       Date:  2019-01-22

Review 4.  Effects of hypothermia on pharmacokinetics and pharmacodynamics: a systematic review of preclinical and clinical studies.

Authors:  Marcel P H van den Broek; Floris Groenendaal; Antoine C G Egberts; Carin M A Rademaker
Journal:  Clin Pharmacokinet       Date:  2010-05       Impact factor: 6.447

5.  Cardiac arrest and therapeutic hypothermia decrease isoform-specific cytochrome P450 drug metabolism.

Authors:  Jiangquan Zhou; Philip E Empey; Robert R Bies; Patrick M Kochanek; Samuel M Poloyac
Journal:  Drug Metab Dispos       Date:  2011-08-25       Impact factor: 3.922

Review 6.  The Implementation of Targeted Temperature Management: An Evidence-Based Guideline from the Neurocritical Care Society.

Authors:  Lori Kennedy Madden; Michelle Hill; Teresa L May; Theresa Human; Mary McKenna Guanci; Judith Jacobi; Melissa V Moreda; Neeraj Badjatia
Journal:  Neurocrit Care       Date:  2017-12       Impact factor: 3.210

7.  The impact of extracorporeal life support and hypothermia on drug disposition in critically ill infants and children.

Authors:  Enno D Wildschut; Annewil van Saet; Pavla Pokorna; Maurice J Ahsman; John N Van den Anker; Dick Tibboel
Journal:  Pediatr Clin North Am       Date:  2012-08-29       Impact factor: 3.278

8.  Drug dosing during hypothermia: to adjust, or not to adjust, that is the question.

Authors:  Samuel M Poloyac; Philip E Empey
Journal:  Pediatr Crit Care Med       Date:  2013-02       Impact factor: 3.624

9.  Moderate hypothermia prevents cardiac arrest-mediated suppression of drug metabolism and induction of interleukin-6 in rats.

Authors:  Michael A Tortorici; Ying Mu; Patrick M Kochanek; Wen Xie; Samuel M Poloyac
Journal:  Crit Care Med       Date:  2009-01       Impact factor: 7.598

10.  Therapeutic hypothermia decreases phenytoin elimination in children with traumatic brain injury.

Authors:  Philip E Empey; Nieves Velez de Mendizabal; Michael J Bell; Robert R Bies; Kacey B Anderson; Patrick M Kochanek; P David Adelson; Samuel M Poloyac
Journal:  Crit Care Med       Date:  2013-10       Impact factor: 7.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.